Matches in Nanopublications for { <http://rdf.disgenet.org/resource/nanopub/NP753473.RAVGghZlCgiNu-J-LfIVPvNrhm0dLiwodhZBGVJSlvpGU130_assertion> ?p ?o ?g. }
Showing items 1 to 6 of
6
with 100 items per page.
- NP753473.RAVGghZlCgiNu-J-LfIVPvNrhm0dLiwodhZBGVJSlvpGU130_assertion type Assertion NP753473.RAVGghZlCgiNu-J-LfIVPvNrhm0dLiwodhZBGVJSlvpGU130_head.
- NP753473.RAVGghZlCgiNu-J-LfIVPvNrhm0dLiwodhZBGVJSlvpGU130_assertion description "[Moreover, the detection of the TP53 R337H variant in our series and the fact that this variant has a founder effect in our population prompted us to suggest that all female breast cancer patients with clinical criteria for HBOC and negative for BRCA1/2 genes should be tested for the TP53 R337H variant.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP753473.RAVGghZlCgiNu-J-LfIVPvNrhm0dLiwodhZBGVJSlvpGU130_provenance.
- NP753473.RAVGghZlCgiNu-J-LfIVPvNrhm0dLiwodhZBGVJSlvpGU130_assertion evidence source_evidence_literature NP753473.RAVGghZlCgiNu-J-LfIVPvNrhm0dLiwodhZBGVJSlvpGU130_provenance.
- NP753473.RAVGghZlCgiNu-J-LfIVPvNrhm0dLiwodhZBGVJSlvpGU130_assertion SIO_000772 24884479 NP753473.RAVGghZlCgiNu-J-LfIVPvNrhm0dLiwodhZBGVJSlvpGU130_provenance.
- NP753473.RAVGghZlCgiNu-J-LfIVPvNrhm0dLiwodhZBGVJSlvpGU130_assertion wasDerivedFrom befree-20150227 NP753473.RAVGghZlCgiNu-J-LfIVPvNrhm0dLiwodhZBGVJSlvpGU130_provenance.
- NP753473.RAVGghZlCgiNu-J-LfIVPvNrhm0dLiwodhZBGVJSlvpGU130_assertion wasGeneratedBy ECO_0000203 NP753473.RAVGghZlCgiNu-J-LfIVPvNrhm0dLiwodhZBGVJSlvpGU130_provenance.